Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study
Psychedelic Medicine · 01.09.2026 · 4 (3) · 222-230
DOI: 10.1177/28314425251404460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychedelic Medicine, online erschienen am 09.12.2025. Verfasst von Anthony L Back und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington, Seattle, Washington, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Steven and Alexandra Cohen Foundation.
Themen: Depression
Abstract (Originalsprache)
Background
Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to date have studied individual models of psilocybin therapy, but group models may offer increased access and benefits of community.
Purpose
This technical report describes a group facilitation model developed for an food and drug administration (FDA)-approved Phase 1 to 2 clinical trial that recruited people with metastatic cancer who had moderate or severe symptoms of anxiety or depression in which psilocybin was administered at a 3-day, in-person retreat.
Results
The facilitation model we developed for this intervention is based on anthropological studies of ritual, specifically rites of passage, to develop a secular ritual with therapeutic aims. Using rites of passage terminology, “separation” corresponds to preparation, “liminal” corresponds to the psilocybin dosing session, and “reincorporation” corresponds to integration. In our usage, the term “ritual” refers to intentionally structured, symbolic acts that embody and reinforce shared meaning, guiding participants through experiences that may otherwise feel unbounded or overwhelming. In the group psilocybin retreat model, ritual functions both psychologically—by supporting emotional regulation, orientation, and meaning-making—and communally—by embedding the individual’s process within a shared field of intention and care.
Conclusion
To our knowledge this is the first FDA-approved clinical trial of a secular ritual-based group facilitation model for psychedelic therapy that is associated with empirically demonstrated safety and efficacy outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Washington, Seattle, Washington, USA.
- Orion Center for Integrative Medicine, Seattle, Washington, USA.
- Private Practice, Squamish, British Columbia, USA.
- Harmony Retreats, Poulsbo, WA, USA.
- Fred Hutch Cancer Center, Seattle, WA, USA.
- Seattle Mindfulness Center, Seattle, WA, USA.
ORCID-Profile: Anthony L Back
Förderung
- Steven and Alexandra Cohen Foundation
Zitieren
APA
Back, A. L., McGregor, B. A., Billingsley, L., Blom, D., Callan, G., Myers, S., Guy, J., Kumar, S., Layer, M., Levin, J., Perez, J., Thompson, P., Salmonson, K., Whinney, J., & Thorn, L. L. (2026). Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study. Psychedelic Medicine, 4(3), 222-230. https://doi.org/10.1177/28314425251404460
Vancouver
Back AL, McGregor BA, Billingsley L, Blom D, Callan G, Myers S, et al. Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study. Psychedelic Medicine. 2026;4(3):222-230. doi:10.1177/28314425251404460
BibTeX
@article{Back2026,
author = {Back, Anthony L and McGregor, Bonnie A and Billingsley, Lindsay and Blom, Dianna and Callan, George and Myers, Susanna and Guy, John and Kumar, Sameet and Layer, Melissa and Levin, Jackie and Perez, Juliana and Thompson, Peter and Salmonson, Kathy and Whinney, Joseph and Thorn, Leslie Lazar},
title = {Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study},
journal = {Psychedelic Medicine},
year = {2026},
volume = {4},
number = {3},
pages = {222--230},
doi = {10.1177/28314425251404460}
}
EUVIMED